We are live on ! Find out more
SPRO icon

Spero Therapeutics

79 hedge funds and large institutions have $15.5M invested in Spero Therapeutics in 2022 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 20 increasing their positions, 22 reducing their positions, and 35 closing their positions.

New
Increased
Maintained
Reduced
Closed

1.23% more ownership

Funds ownership: 62.63%63.86% (+1.2%)

6% more call options, than puts

Call options by funds: $36K | Put options by funds: $34K

9% less repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 22

21% less funds holding

Funds holding: 10079 (-21)

50% less funds holding in top 10

Funds holding in top 10: 21 (-1)

54% less first-time investments, than exits

New positions opened: 16 | Existing positions closed: 35

91% less capital invested

Capital invested by funds: $180M → $15.5M (-$164M)

Holders
79
Holders Change
-21
Holders Change %
-21%
% of All Funds
1.33%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
16
Increased
20
Reduced
22
Closed
35
Calls
$36K
Puts
$34K
Net Calls
+$2K
Net Calls Change
-$202K

SPRO Hedge Fund Activity: Q2 2022 in Review

79 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Spero Therapeutics (SPRO) for Q2 2022, worth a combined $15.5M — down 91% from $180M a quarter earlier.

Sellers outnumbered buyers: 35 funds closed out of SPRO and 16 opened new positions — a net loss of 19 holders — while 22 trimmed existing stakes and 20 added.

The largest buyer was BVF Inc, adding an estimated $4.37M. The largest seller was Ameriprise, exiting entirely with an estimated $5.1M sold.

  • 79 institutional investors held Spero Therapeutics (SPRO) as of Q2 2022, down from 100 in Q1 2022.
  • Funds reported $15.5M of Spero Therapeutics stock for Q2 2022, down 91% quarter-over-quarter.
  • 16 funds opened new Spero Therapeutics positions in Q2 2022 and 35 closed out, a net change of -19 holders.
  • The largest Spero Therapeutics buyer in Q2 2022 was BVF Inc, an estimated $4.37M added.
  • The largest Spero Therapeutics seller in Q2 2022 was Ameriprise, an estimated $5.1M sold.

Based on aggregated 13F filings for Q2 2022.